annb0t
Top 20
CSL is on track to file for regulatory approvals at the end of the current fiscal year and will present full data set at an upcoming scientific congress
KING OF PRUSSIA, Pa., Aug. 17, 2022 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced positive top-line Phase 3 results for garadacimab (CSL312), the company's investigational first-in-class monoclonal antibody inhibiting Factor XIIa being developed as a long-term preventive treatment for patients with here...
>>> Read more: CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
KING OF PRUSSIA, Pa., Aug. 17, 2022 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced positive top-line Phase 3 results for garadacimab (CSL312), the company's investigational first-in-class monoclonal antibody inhibiting Factor XIIa being developed as a long-term preventive treatment for patients with here...
>>> Read more: CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
